ArticleCancers2023

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.

Jennifer A Woyach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.